Oncolytics Biotech Inc Dossier - Source-backed chat

Oncolytics Biotech Inc

ONCYNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.09

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.64Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $81.8M

Enterprise Value $77.6M

Shares Outstanding 124.1M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic platform. The company's investment thesis centers on the clinical potential of pelareorep to convert immunologically 'cold' tumors 'hot' across multiple gastrointestinal cancers. Recent regulatory milestones, including FDA Fast Track Designation in second-line KRAS-mutant MSS metastatic colorectal cancer (mCRC) and alignment on a Phase 3 trial design for pancreatic cancer, provide a clear development pathway. While the company faces near-term going-concern risks due to a limited cash runway, its strong clinical efficacy data—such as doubling or tripling historical survival and response benchmarks in mCRC—makes it an attractive target for strategic partnerships or acquisition, especially following the appointment of Steve Glover to the Board.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.87

Mean target$5.05

High · most bullish analyst$10.03

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.7620%

Preliminary data from the REO-033 trial fails to replicate prior Phase 2 efficacy, showing marginal or no benefit over the control arm. Concurrently, the company is forced to execute highly dilutive equity raises under its ATM facility to sustain operations, severely depressing the share price as cash reserves dwindle without a strategic partner.

Base CaseCentral scenario

$5.4355%

Oncolytics successfully manages its cash runway through controlled utilization of its ATM facility and strategic cost management. Preliminary Phase 2 REO-033 data by year-end 2026 confirms a statistically significant improvement in objective response rates (ORR) and progression-free survival (PFS) over standard-of-care. The company initiates its planned Phase 3 pancreatic cancer trial with a partner, supporting a valuation aligned with consensus analyst targets.

Bull CaseUpside scenario

$10.0025%

The randomized Phase 2 REO-033 trial in second-line RAS-mutated MSS mCRC delivers preliminary data by year-end 2026 that replicates the outstanding efficacy of the prior REO-022 study (27 months median OS vs. 11.2 months standard-of-care). This triggers a major global co-development partnership with a tier-one pharmaceutical company, securing non-dilutive upfront capital, eliminating going-concern risk, and driving the stock toward high-end analyst targets.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Compelling clinical efficacy data showing pelareorep doubles or triples historical survival and response benchmarks in difficult-to-treat, immunologically cold gastrointestinal tumors.
FDA Fast Track Designation in both metastatic pancreatic and colorectal cancers, providing accelerated regulatory pathways and frequent FDA communication.
Strong intellectual property protection with a newly secured U.S. patent protecting commercial manufacturing of pelareorep into 2044.
Strategic board and executive additions, including Steve Glover (former Chairman of Ambrx Biopharma, acquired for $2B), enhancing transaction and partnership potential.

Key Investment Risks

Severe going-concern risk with cash and cash equivalents of $5.5 million as of March 31, 2026, which is insufficient to fund operations for the next twelve months without additional financing.
High risk of shareholder dilution due to active at-the-market (ATM) equity distribution arrangements to support clinical development.
Clinical development risk inherent in oncology trials, where preliminary early-phase success may fail to be replicated in larger randomized controlled trials.

Thesis Invalidation Triggers

Failure of the REO-033 Phase 2 trial to meet its primary endpoint of objective response rate (ORR) or showing unfavorable safety signals.
Inability to secure a strategic development partner or additional financing within the next 6 months, leading to an operational halt or distressed asset sale.
Rejection or significant delay of the manufacturing patent application by the USPTO in Q3 2026, reducing the commercial exclusivity runway.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.